phase 2_initiation
saveTianFang Pharmaceutical Co — diclofenac sodium DR (Phase II Trial Initiation)
community read0 votes
Therapy area: Central Nervous System, Immunology, Musculoskeletal Disorders, Other Diseases, Women's Health. Indication: Dental Pain (Toothache/Tooth Pain), Dysmenorrhea, Gouty Arthritis (Gout), Injury, Myalgia (Muscle Pain), Osteoarthritis, Pain, Post-Operative Pain, Rheumatic Disorders, Rheumatoid Arthritis, Spondyloarthritis (Spondyloarthropathy), Tenosynovitis
Data sources
globaldata
Found something off?
drug timeline · 8
- approvalDICLOFENAC SODIUM — FDA approvalDec 31, 2025 · 283d ago
- approvalDICLOFENAC SODIUM — FDA approvalNov 21, 2024 · 688d ago
- approvalDICLOFENAC SODIUM — FDA approvalApr 28, 2021 · 1991d ago
- approvalDICLOFENAC SODIUM — FDA approvalMar 29, 2021 · 2021d ago
- approvalDICLOFENAC SODIUM — FDA approvalMay 9, 2016 · 3806d ago
- approvalDICLOFENAC SODIUM — FDA approvalNov 28, 2014 · 4334d ago
- approvalDICLOFENAC SODIUM — FDA approvalMar 19, 2010 · 6049d ago
- approvalDICLOFENAC SODIUM — FDA approvalDec 20, 2007 · 6869d ago
🐶 often sniffed alongside
top 8- tagApproval26 co-mentions · 13 sources
- drugDictor19 co-mentions · 16 sources
- drugdiclofenac sodium ER19 co-mentions · 16 sources
- drugdiclofenac sodium SR19 co-mentions · 16 sources
- drugPennsaid19 co-mentions · 16 sources
- drugdiclofenac sodium DR19 co-mentions · 16 sources
- drugdiclofenac19 co-mentions · 16 sources
- drugdiclofenac ER19 co-mentions · 16 sources
comments(0)
5-min edit window · permanent after that